IDEXX Laboratories (FRA:IX1) NonCurrent Deferred Liabilities: €67 Mil (As of Mar. 2026)


FRA:IX1 IDEXX Laboratories Inc FRA:IX1
98 GF Score
Price €486.20
GF Value €546.15
Valuation Modestly Undervalued
View Full Analysis

What is IDEXX Laboratories NonCurrent Deferred Liabilities?

IDEXX Laboratories FRA:IX1 +0.14% 98 NonCurrent Deferred Liabilities is €67 Mil as of Mar. 2026. GuruFocus rates FRA:IX1 with a GF Score™ of 98/100 and a GF Value™ of €546.15 (Modestly Undervalued).

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

IDEXX Laboratories's non-current deferred liabilities for the quarter that ended in Mar. 2026 was €67 Mil.

IDEXX Laboratories NonCurrent Deferred Liabilities Related Terms

IDEXX Laboratories NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for IDEXX Laboratories's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDEXX Laboratories NonCurrent Deferred Liabilities Chart

IDEXX Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.35 36.83 32.80 36.53 54.69

IDEXX Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.31 29.35 29.63 54.69 66.53
FRA:IX1
98GF Score
IDEXX Laboratories Inc FRA:IX1
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of €67 Mil mean?
IDEXX Laboratories (FRA:IX1) has a NonCurrent Deferred Liabilities of €67 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on IDEXX Laboratories and its competitors.
Is IDEXX Laboratories' NonCurrent Deferred Liabilities too high?
IDEXX Laboratories' current NonCurrent Deferred Liabilities is €67 Mil. Overall, IDEXX Laboratories has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' NonCurrent Deferred Liabilities compare to A and NTRA?
IDEXX Laboratories' NonCurrent Deferred Liabilities of €67 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Medical Diagnostics & Research company?
A good NonCurrent Deferred Liabilities depends on the Medical Diagnostics & Research industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on IDEXX Laboratories and its competitors. IDEXX Laboratories's current NonCurrent Deferred Liabilities is €67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €546.15, compared to a current price of €486.20 — trading 11% below its estimated fair value. The current NonCurrent Deferred Liabilities is €67 Mil. IDEXX Laboratories' overall GF Score™ is 98/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current NonCurrent Deferred Liabilities is €67 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?

Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued. The current stock price of €486.20 is trading 11% below its estimated GF Value™ of €546.15. GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.

Key valuation signals for FRA:IX1:

  • NonCurrent Deferred Liabilities: €67 Mil
  • GF Value™: €546.15 vs. price of €486.20 (11% below fair value)
  • GF Score™: 98/100

No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IDEXX Laboratories Business Description

Address One IDEXX Drive, Westbrook, ME, USA, 04092
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
98GF Score

Get the complete analysis for FRA:IX1

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€486.20
Price
€546.15
GF Value